These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 34093519)

  • 21. Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.
    Liu Y; Chen X; Wang D; Li H; Huang J; Zhang Z; Qiao Y; Zhang H; Zeng Y; Tang C; Yang S; Wan X; Chen YH; Zhang Y
    J Immunother; 2018; 41(9):406-410. PubMed ID: 30198955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.
    Hughes AD; Teachey DT; Diorio C
    Semin Immunopathol; 2024 Jul; 46(3-4):5. PubMed ID: 39012374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
    Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
    Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.
    Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T
    Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.
    Zhang C; Wang XQ; Zhang RL; Liu F; Wang Y; Yan ZL; Song YP; Yang T; Li P; Wang Z; Ma YY; Gao L; Liu Y; Gao L; Kong PY; Liu J; Tan X; Zhong JF; Chen YQ; Liang AB; Ren JH; Li ZY; Cao J; Gao QL; Zhou J; Gao Y; Zhang D; Fan FY; Han MZ; Gale RP; Zhang X
    Leukemia; 2021 Jun; 35(6):1563-1570. PubMed ID: 33077866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies.
    Rivera AM; May S; Lei M; Qualls S; Bushey K; Rubin DB; Barra ME
    Crit Care Nurs Q; 2020; 43(2):191-204. PubMed ID: 32084062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.
    Foster MC; Savoldo B; Lau W; Rubinos C; Grover N; Armistead P; Coghill J; Hagan RS; Morrison K; Buchanan FB; Cheng C; Laing S; Ivanova A; West J; Foster A; Serody J; Dotti G
    Blood; 2021 Jun; 137(23):3306-3309. PubMed ID: 33624095
    [No Abstract]   [Full Text] [Related]  

  • 31. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
    Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
    [No Abstract]   [Full Text] [Related]  

  • 33. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.
    Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y
    J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine Release Syndrome after Treatment of Anti-CD19 CAR-T Therapy with IL-6 Knocking Down in Patients with Central Nervous System B-cell Acute Lymphocytic Leukemia.
    Mao Y; Xu X
    Ann Clin Lab Sci; 2021 Nov; 51(6):790-794. PubMed ID: 34921032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy.
    Walton ZE; Frigault MJ; Maus MV
    Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular therapy: Immune-related complications.
    Oved JH; Barrett DM; Teachey DT
    Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome.
    Stahl K; Schmidt BMW; Hoeper MM; Skripuletz T; Möhn N; Beutel G; Eder M; Welte T; Ganser A; Falk CS; Koenecke C; David S
    J Crit Care; 2020 Jun; 57():124-129. PubMed ID: 32113143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment.
    Liu D; Xu X; Dai Y; Zhao X; Bao S; Ma W; Zha L; Liu S; Liu Y; Zheng J; Shi M
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival.
    Julamanee J; Terakura S; Umemura K; Adachi Y; Miyao K; Okuno S; Takagi E; Sakai T; Koyama D; Goto T; Hanajiri R; Hudecek M; Steinberger P; Leitner J; Nishida T; Murata M; Kiyoi H
    Mol Ther; 2021 Sep; 29(9):2677-2690. PubMed ID: 33940156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.